Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Friday 2 October →